Excellent presentation, recommend to watch for all shareholders, best and comprehensive presentation to date, IMO.
Clearly our vast library, globally the most diverse, is now coming commercially into play, low toxicity, multiple target markets in particular CNS.
Utility into a wide range of genetic diseases. The ability to match particular peptides with the right PPMOs to such degree of accuracy is PYCs outstanding differentiator, achieving higher accuracy at lower doses.
CNS drug candidate reveal is again confirmed, no delays estimated, which is a good
indicator that company sticks to timelines.
First hint at additional areas of unmet need outside ocular and CNS, kidney, heart, diaphram etc.
Larger animal study results shared shortly, next two weeks.
The readouts shared shortly will be a milestone for the applicability of the entire program, apart the VP001.
This, in my opinion, explains the potentail positioning of investors and developments partners prior to those readouts.
Interesting times ahead until about mid Oct.
all IMO
PYC Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)